Praveen Tipirneni, Morphic CEO

Ab­b­Vie cuts away part of its part­ner­ship with Mor­phic on in­te­grin re­search for fi­bro­sis

De­spite a qui­et few years, Mor­phic Ther­a­peu­tic was once a buzzy biotech look­ing to move in­te­grin re­search in­to the next gen­er­a­tion. Now, a drug gi­ant part­ner is qui­et­ly ditch­ing part of its col­lab­o­ra­tion with the biotech.

Ab­b­Vie has de­cid­ed to dis­con­tin­ue re­search in­to the αVβ6 in­te­grin as part of a deal with Mor­phic dat­ing back to 2018, the biotech said Thurs­day.

Snuck qui­et­ly in­to an earn­ings re­lease, Mor­phic said Ab­b­Vie opt­ed to walk on that part of the col­lab­o­ra­tion but didn’t of­fer any spe­cif­ic rea­son why. The com­pa­ny not­ed that re­search in­to oth­er in­te­grin tar­gets is still on­go­ing de­spite the set­back.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

San Diego, CA, USA